References

10.1056/nejmoa1200690

10.1056/nejmoa1200690 · External reference

10.1016/s1470-2045(16)30126-7

10.1016/s1470-2045(16)30126-7 · External reference

10.1056/nejmoa1003466

10.1056/nejmoa1003466 · External reference

10.1016/j.oraloncology.2018.04.008

10.1016/j.oraloncology.2018.04.008 · External reference

10.1056/nejmoa1602252

10.1056/nejmoa1602252 · External reference

10.1056/nejmra1703481

10.1056/nejmra1703481 · External reference

10.1111/his.13118

10.1111/his.13118 · External reference

10.1200/jco.21.01440

10.1200/jco.21.01440 · External reference

10.1200/jco.2017.77.6385

10.1200/jco.2017.77.6385 · External reference

Anti-PD1-induced collagenous colitis in a melanoma patient

10.1097/cmr.0000000000000252 · 2016 · External reference

10.1136/gutjnl-2018-316948

10.1136/gutjnl-2018-316948 · External reference

Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist

10.14694/edbook_am.2012.32.79 · 2012 · External reference

Remitting Seronegative Symmetrical Synovitis with Pitting Edema: A Case Report of an Immune-Related Adverse Event following Surgery

10.1159/000532004 · 2023 · External reference

Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in locally advanced non-small cell lung cancer: a case report

10.21037/tlcr-21-603 · 2021 · External reference

Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report

10.1186/s40792-021-01346-w · 2021 · External reference

Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors

10.1371/journal.pone.0306995 · 2024 · External reference

10.1158/1078-0432.ccr-21-1283

10.1158/1078-0432.ccr-21-1283 · External reference